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LRRK2a progressive neurodegenerative movement disorder with unknown etiology.
It is marked by widespread neurodegeneration in the brain with profound loss of A9 midbrain
dopaminergic neurons in substantia nigra pars compacta. Several theories of biochemical abnormalities
have been linked to pathogenesis of PD of which mitochondrial dysfunction due to an impairment of
mitochondrial complex I and subsequent oxidative stress seems to take the center stage in experimental
models of PD and in postmortem tissues of sporadic forms of illness. Recent identiﬁcation of speciﬁc gene
mutations and their inﬂuence on mitochondrial functions has further reinforced the relevance of
mitochondrial abnormalities in disease pathogenesis. In both sporadic and familial forms of PD abnormal
mitochondrial paradigms associated with disease include impaired functioning of the mitochondrial
electron transport chain, aging associated damage to mitochondrial DNA, impaired calcium buffering, and
anomalies in mitochondrial morphology and dynamics. Here we provide an overview of speciﬁc
mitochondrial functions affected in sporadic and familial PD that play a role in disease pathogenesis. We
propose to utilize these gained insights to further streamline and focus the research to better understand
mitochondria's role in disease development and exploit potential mitochondrial targets for therapeutic
interventions in PD pathogenesis.
Published by Elsevier B.V.1. Introduction
Mitochondria, the power house of living cells and regulators in cell
survival and death are especially complex and delicate organelles.
Mitochondria easily succumb to diverse assaults either generated in
situ or those imposed from extracellular environment. Mitochondrial
dysfunction results in a dwindling supply of cellular energy, a failure
in maintaining cellular homeostasis, and activation of cell death
pathways which could underlie selective dopaminergic neurodegen-
eration in Parkinson's disease (PD) [1]. PD is characterized patholo-
gically by the loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc), reduction of dopamine and its metabolite
levels in the basal ganglia and formation of Lewy bodies [2]. Clinically
PD patients manifest symptoms of progressive rigidity, bradykinesia,
tremor and postural instability [3,4] and depend solely on sympto-
matic relief treatments [5]. To date there is no cure for PD, the
etiopathology of PD is unresolved, and hence the quest to deﬁne
diseasemechanisms continues. Whether mitochondrial dysfunction is
the cause or effect of PD pathogenesis is debatable. In this review we
have provided an update of PD research pursued over the last three
decades that underpins the participation of mitochondria in the
dopaminergic neuronal demise in PD.1 212 746 8276.
as).
B.V.2. Mitochondrial dysfunction in the idiopathic form of disease
The causes to the idiopathic form of PD accounting for almost 95%
of cases are unknown, and several theories are suggested in the
etiology of the disease. In this section we review the most relevant
features involved in mitochondrial dysfunction that are associated
with the disease.
2.1. Mitochondrial electron transport chain complexes in PD
The seminal discovery that MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) causes PD-like symptoms in humans [6] and the
ensuing rapid unraveling of its molecular mechanism of toxicity
strongly stimulated the interest of PD research community to the role
of mitochondria in PD pathology. In non-human primates, MPTP
intoxication recapitulates most of the clinical and pathological
hallmarks of PD except for the presence of Lewy bodies [7–9]. The
revelation of MPTP mechanisms has resulted in a gold mine of
information regarding the involvement of mitochondria and led to
subsequent development of other toxin-induced animal models of PD.
MPTP is metabolized to its toxic form MPP+ (1-methyl-4-phenylpyr-
idinium ion) by mitochondrial monoamine oxidase (MAO) [10],
speciﬁcally by MAO B [11] and is rapidly concentrated in the
mitochondria by an energy-dependent process [12]. Once accumu-
lated, it speciﬁcally inhibits the oxidation of NAD (nicotinamide
adenine dinucleotide) -linked substrates [13] by blocking the electron
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somewhere in the proximity of its quinone binding site [14]. It also
inhibits the activity of a key TCA (tricarboxylic acid) enzyme KGDHC
(α-ketoglutarate dehydrogenase complex), thereby impairing the ATP
synthesis and inducing “energy crisis” in vitro [15] and in vivo [16]. The
rather selective toxicity of MPP+ to dopaminergic neurons in SN
(substantia nigra) was explained by the fact that MPP+ is selectively
accumulated by the dopamine uptake system involving the dopamine
transporters (DAT) [17]. Human platelets which also express DAT [18]
have been shown to accumulate MPP+with high efﬁciency and suffer
frommitochondrial failure as a result of MPP+ exposure [19]. Human
platelets also contain high levels of MAO B and share a number of
properties with aminergic neurons including receptors, uptake sites
and storage granules for amine neurotransmitters. As platelets are
more available for research than PD brain samples or muscle biopsy,
they were a natural choice of PD tissue samples for earlier studies on
the status of complex I in PD. Several laboratories reported low
complex I activities in either PD platelet homogenates or mitochon-
dria isolated from PD platelets, although the degree of its inhibition
varied within a wide range. The activities of other respiratory chain
complexes in PD platelets were even more variable, that is some
laboratories found impaired complex II [20], complex II + complex III
[21], and complex IV activities [22], whereas others reported a
selective complex I inhibition [21,23] (See Table 1 for details). It isTable 1
Impaired activity of ETC complexes in PD
Merged cells indicate that the reported activity was measured over a span of two or
more ETC complexes, e.g. complex II+complex III or complex I+III. Changes in
activities are presented in % from control; numbers indicate the number of individual
samples assayed; “m” or “c” indicates whether isolated mitochondria (m) or crude
homogenates (c) were used for assessing the enzyme activities; n.d. stands for “no
difference found”; “n.a.” stands for “not assessed”.noteworthy that no distinction was made between familial PD
patients and sporadic PD patients in these earlier studies, and their
treatment status had not always been reported. The latter is of
importance because some neuroleptics are known to inhibit complex I
in vitro [24], and L-dopa (levo-dopa) treated rats also exhibit lowered
complex I activity in brain mitochondria [25]. However, these factors
were accounted for in the study by Haas and colleagues, who found a
decreased activity of complex I and other ETC complexes in platelets
from untreated PD patients [21]. Additionally about an equal number
of studies and in particular more recent ones did not ﬁnd any
inhibition in complex I or other ETC complexes in platelets isolated
from either sporadic or familial PD patients which were either
receiving treatment or untreated at the time of analysis [26–31]. There
is no consensus in most of the reported data on ETC activities in other
PD tissues (Table 1), with earlier reports ﬁnding ETC deﬁciencies
whereas later reports contradicting these ﬁndings. Earlier reports
[29,32–34] point to a speciﬁc deﬁciency in complex I activity in SN but
not in other brain sub-regions. However, more recently lowered
complex I activity was shown in puriﬁed mitochondria isolated from
PD frontal cortex [35,36]. A selective decrease in a number of subunits
in complex I was also demonstrated in PD brain [37]. Others could not
conﬁrm this ﬁnding [38], but a recent study also reported some
abnormalities in assembly and oxidation of complex I subunits in PD
cortex mitochondria [36]. Several studies showed impaired complex I,
II+III, and IV in PD muscle [39–41], whereas others reported no
differences [29,42,43], and ﬁndings on the ETC deﬁciency in PD
lymphocytes [20,44] are counter-balanced by the evidence on the
absence of such deﬁciencies [45]. Such inconsistency in the experi-
mental data could likely be explained by signiﬁcant methodological
differences in all these studies, e.g. difﬁculties in obtaining the
relevant tissue samples, individual variability of PD patients andmany
other factors, as was recently suggested [35]. Most of these problems
can surely be overcome in the future studies, however it is felt that a
deﬁnite and reliable answer to whether there is ETC dysfunction in PD
mitochondria can not be obtained by an individual laboratory. It likely
will require a coordinated effort of an international consortium, well
standardized assay procedures, and a statistically meaningful number
of thoroughly characterized tissue samples. As it stands now, the
deﬁciency in ETC complexes appears to be at least an idiopathic
molecular feature of PD, but the questionwhether it ﬁrmly belongs to
other molecular landmarks of PD neuropathology can not be
answered with certainty. One could argue whether ETC deﬁciency is
etiological in PD. However the presence of reduced complex I function
in less affected regions in the CNS and in platelets indicates that it
could be an early pathogenic event in PD. Ample data strongly suggest
that toxin-induced ETC disruption per se is sufﬁcient to trigger the
death of nigrostriatal neurons and to cause PD-like symptoms in
animals and humans. Thus, despite discrepancies in ETC functions
reported from various laboratories, a systemic complex I deﬁciency
might be a predominant feature in PD pathogenesis.
2.2. Pesticidal exposure and its link to mitochondrial dysfunction
Epidemiological studies have clearly established the role of
environmental factors posing an increased risk of developing PD
[46]. Earlier epidemiological evidence from twin studies and more
recently published genome-wide single nucleotide polymorphism
analyses of a population cohort of parkinsonian patients strongly
suggest that idiopathic PD does not develop due to genetic heritability
[47,48]. This, along with geographic variations in PD incidence,
suggests that sporadic PD is most likely because of environmental
factors, perhaps in combination with genetic susceptibilities. Expo-
sure to agricultural chemicals such as pesticides has been postulated
as a potential environmental risk factor for the disease [49]. This
relationship of pesticide exposure and PD appears strongest for
exposure to herbicides and insecticides, especially following long
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from a Taiwanese study which showed that exposure to paraquat for
more than 20 years was associated with PD [50].
Paraquat (1,1′-dimethyl-4,4′-bipyridinium, CAS# 4685-14-7)
belongs to a class of quaternary ammonium herbicides. Chemically,
paraquat closely resemblesMPTP and it was tested as a PDmodel soon
after the discovery of MPTP [51]. This extensively used herbicide has
been linked to PD in epidemiological surveys [52], and a case study
reported parkinsonism in a farmer acutely exposed to the related
herbicide diquat dibromide [53]. In rodents, paraquat caused selective
degeneration of dopaminergic neurons [54], dopamine depletion, α-
synuclein protein aggregation and increased oxidative stress [55].
Paraquat also induced an increase in the α-synuclein level in SN and
frontal cortex and caused intraneuronal aggregation of α-synuclein in
the SNpc [56].
Although both MPP+ and paraquat inhibit mitochondrial complex
I, there are substantial differences in the action of these toxins [57].
Paraquat entry into neurons is not mediated by the dopamine
transporter [58], and it does not bind to rat and mouse striatal
dopamine D1 and D2 receptors. Therefore, there is no molecular basis
for this compound to accumulate selectively in the SN dopaminergic
neurons, as is the case with MPP+. Paraquat also has a much lower
binding afﬁnity toward complex I. In vivo exposure to MPTP and
rotenone, but not paraquat, inhibited binding of 3H-dihydrorotenone
to complex I in brain mitochondria [57]. Similar to MPP+, paraquat
induces signiﬁcant ROS production through redox cycling [59]. To
note, we have compared in vitro ROS-inducing efﬁciency of complex I-
targeting pesticides MPP+ and pyridaben with that of paraquat, and
found that the latter is a more potent (∼10 folds) ROS inducer.
Moreover, the onset of ROS production by this compound in isolated
mouse brain mitochondria actually preceded the inhibition of
complex I, which was not the case with pyridaben and MPP+ (our
unpublished results). Taking into account that paraquat can generate
ROS in non-mitochondrial enzymatic reactions [60], we think it is
quite possible that the mechanism of paraquat toxicity to SN neurons
is entirely different from that of MPP+. This suggests that paraquat
kill cells through failure in antioxidant defenses and oxidative damage
to cytosolic proteins [61], whereas MPP+ causes toxicity through
bioenergetics failure. However, in both scenarios mitochondria are
primary mediators of cell death as they are the major source of
paraquat-induced ROS production in the brain [62].
It was noted that geographic overlap in use of paraquat and another
ETC toxin, maneb could indicate a multiple-hit environmental model in
which both compounds act synergistically on the dopaminergic system
[54,63,64]. Maneb ([[2-[(dithiocarboxy) amino] ethyl] carbamo-
dithioato]](2-)-κS,κS′]manganese, CAS# 12427-38-2) belongs to a
class of manganese-containing dithiocarbamate fungicides. Exposure
to maneb has been associated with parkinsonism [65]. Laboratory
studies suggest that dithiocarbamates can cause dopamine depletion
and inducedegenerationof dopaminergic neurons [55]. Therehavebeen
case reports of parkinsonism in agricultural workers exposed to maneb
[65,66]. In mitochondria, maneb binds to complex III, thereby blocking
the oxidative phosphorylation, inhibiting respiration and inducing ROS
generation [67]. Maneb also inhibits the ubiquitin proteasome pathway
[68]. Thus, maneb-induced mitochondrial impairment could be aug-
mented by a derangement in protein degradation machinery.
In rodents, simultaneous injections of both paraquat and maneb
exhibited higher toxicity than injections of each chemical alone
[54,63,64], with nigrostriatal degeneration and other pathological
features that closely resemble sporadic PD. Recent studies hints that
the mechanism of synergistic action of maneb and paraquat is
modulated by the expression of major mitochondrial pro-apoptotic
proteins. Individually, paraquat and maneb induce Bak-dependent cell
death, but together they trigger Bax-dependent cell death. They do so by
increasing the expression of three strongBak inhibitors, Bﬂ-1, Bcl-xL and
Mcl-1, and by inducing Bax activators that include Bak and Bim [69,70].Recently, rotenone rat models of PD have been developed that
reproduce essential biochemical and behavioral human PD features
such as irreversible cell death of dopamine neurons and formation of
Lewy body-like cytoplasmic inclusions [71–73]. Rotenone is a classical
and reasonably selective inhibitor of mitochondrial complex I. In vitro,
rotenone completely prevents the oxidation of pyruvate and many
other physiological substrates, thereby inhibiting ATP synthesis in
mitochondria. Moreover, rotenone and other complex I inhibitors
stimulate ROS production by mitochondria [74]. To note, mammalian
mitochondrial complex I is a very complex enzyme, composed of at
least 49 individual polypeptides. This enzyme is the proton pump
capable of converting the chemical energy of NADH into the
electrochemical proton gradient across the inner membrane of
mitochondria. Mitochondria utilize the proton gradient to synthesize
ATP. The NADH is derived from multiple reactions of oxidation of
various nutrients in mitochondria; in order to maintain their normal
rates, NADH has to be re-oxidized to NAD+, similar to as it happens in
glycolysis. This reoxidation is catalyzed by complex I, which is
therefore important for both an efﬁcient ATP synthesis and for the
normal functioning of the overall catabolic machinery of mitochon-
dria. Moreover, several of the individual polypeptides comprising
complex I have been shown to interact with non-ETC proteins
participating in other cellular processes. Some of these proteins are
“suspiciously” associated with cell death pathways believed to be
important in PD. For example, a recently discovered component of
complex I called GRIM-19 (gene associated with retinoid-IFN-induced
mortality) physically interacts with a serine proteaseHtrA2/Omi (High
temperature requirement protein A2) and enhances its pro-apoptotic
activity [75]. In humans, point mutations in HtrA2 are a susceptibility
factor for PD (PARK13 locus). Moreover, HtrA2 interacts with a putative
mitochondrial protein kinase PINK1; mutations in the latter are
associated with the PARK6 autosomal recessive locus for susceptibility
to early-onset PD [76]. Upon activation of the p38 stress-sensing
pathway, HtrA2 is phosphorylated in a PINK1-dependent manner at a
residue adjacent to a position found mutated in patients with PD.
HtrA2 phosphorylation is decreased in brains of PD patients carrying
mutations in PINK1. We mentioned these facts here to illustrate that a
simple and common perception that “complex I inhibition causes
bioenergetics impairment causes ATP depletion causes cell death”
might be too simplistic as complex I dysfunction may cause cell death
by another mechanism which is yet to be discovered. In fact, ATP
depletion had been ruled out as a cause of selective neurotoxicity of
rotenone in rodents [77]. Furthermore, a recent study provides some
interesting insights on the role of complex I in mediating cell death.
Deletion of functional Ndufs4, a gene encoding one of the subunits
required for complete assembly and function of complex I led to
abolished complex I activity in midbrain mesencephalic cultures
derived fromNdufs4 knockout mice [78]. However, deletion of Ndufs4
did not affect the survival of dopaminergic neurons in these midbrain
cultures. Interestingly dopaminergic neurons were more sensitive
than other neurons in these cultures to cell death induced by rotenone,
MPP+, or paraquat treatment. Contrary to the expectation, absence of
complex I activity did not rescue dopaminergic neurons, from these
mitochondrial toxins through inhibition of complex I. This study casts
doubt upon the generally accepted notion that complex I is the
primarymechanism of toxicity of PD-linked neurotoxins. These results
have implications on how experimental results using such mitochon-
drial toxins are interpreted in the context of cell death in PD. In this
regard, a recent study provides new insights into the mechanism of
rotenone-induced neurotoxicity and the role of complex I in vivo [79].
This study used the rotenone toxicity rat model combined with a
stereotactic viral delivery of complex I “substitute”, enzyme called
“alternative NADH dehydrogenase” (Ndi1). The latter is a single-
polypeptide NADH dehydrogenase found in yeast mitochondria that
does not generate proton gradient but catalyzes normal NADH
oxidation. An expression of the Ndi1 protein in the rat SN strongly
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hydroxylase positive dopamine neurons and decreased oxidative
damage to DNA in these neurons [79]. These ﬁndings have two very
signiﬁcant ramiﬁcations. First, it demonstrates that neuronal cell
survival depends on the ability of complex I to re-oxidize mitochon-
drial NADH rather than on its ability to generate proton gradient or its
interaction with other proteins. This greatly contributes to our
understanding of the mechanistic aspects of complex I and ETC
impairments in cell death. Second, this study brightly illustrates that
current knowledge of these mechanistic aspects is, if incomplete,
already sufﬁcient enough to design a mitochondria-targeted in vivo
treatment ameliorating a toxin-induced neuronal death. This devel-
opment brings new hope that therapeutically relevant interventions
for human PD would be possible to design in near future.
2.3. Role of mitochondrial DNA in PD
The fact that cellular organelles such as mitochondria can house
their own DNA has further added to the functional complexity. It is
strongly believed that proximity of mitochondrial DNA (mtDNA) to
ROS generated as a consequence of respiratory chain function could
render mtDNA vulnerable to mutations [80,81]. A dysfunction in
complex I could lead to a defective ROS producing system that in turn
may affect the mtDNA which encodes 7 of the 49 protein subunits of
the complex I enzyme. Strong support for mtDNA encoded defect
comes from studies which showed that complex I defects from PD
platelets are transferable into mitochondrial deﬁcient cybrid cell lines
[82,83]. These defects are associated with increased free radical
production, increased susceptibility to MPP+, and impaired mito-
chondrial calcium buffering [84]. This suggests that the complex I
deﬁcits in PD are inherited either from the mitochondrial genome or
from alteration in somatic mtDNA. In PD, the maternal inheritance
pattern of mtDNA mutation is rare and may be a mere coincidence
[85–87]. However, a number of studies provide genetic evidence that
mtDNA abnormality may contribute to PD pathogenesis. A novel
mitochondrial 12SrRNA point mutation was found in a pedigree with
Parkinsonism, deafness and neuropathy [87]. There is also evidence
for occurrence of Parkinsonism in association with the Leber's optic
atrophy mitochondrial mutation G11778A [88]. Analysis of mtDNA
found no homoplasmic mtDNA point mutations in coding regions in
PD subjects in either DNA isolated from white blood cells or from the
SN [89,90]. Whereas low level heteroplasmic mutations in the ND5
subunit of complex I were reported to be associated with PD, [91] the
level of heteroplasmy was much less than seen in diseases caused by
mtDNA mutations. Contrary to these our recent study found higher
burden of homoplasmic mtDNA mutations in PD subjects from SN of
younger patients who have not lost a signiﬁcant number of
dopaminergic neurons (M Flint Beal unpublished observations).
Human mtDNA exhibits region speciﬁc variation in indigenous
populations [92] that can be organized into phylogenetic trees. The
haplotype J and K are associated with mild uncoupling of mitochon-
dria, allowing adaptation to colder climates, which would lead to
reduced mitochondrial ROS production. Haplotype J, determined by a
single nucleotide polymorphism (SNP) at 10398G and haplotype K in
the control region of mtDNA, reduced the incidence of PD by 50% in
patients of European ancestry [93]. Furthermore in the same study, a
SNP at 9055A of ATP6 reduced the risk in women, and SNP 13708A
within the NADH dehydrogenase 5 gene was protective in individuals
older than 70 years of age (73% reduction). Consistent with these
ﬁndings the haplotype cluster UKJT produced a 22% decrease in the
risk of getting PD [94]. In a Finnish population the super cluster JTIWX
increased the risk of both PD and PDwith dementia. The JTIWX cluster
was associated with a 2 fold increase in non-synonymous substitu-
tions in the mtDNA genes encoding complex I subunits [95].
Additional evidence to the role of mtDNA in PD was found by an
increased proportion of mtDNA deletion observed in PD patients ascompared to age-matched control subjects associated with a decrease
in cytochrome oxidase activity [96,97]. These mutations were
considered somatic as each neuron harbored its own unique set of
mtDNA deletions [97]. On the contrary, such mtDNA deletions in the
nigral neurons have also been reported to be increased in the elderly
human population [98]. Mitochondrial genome sequence from SN of
PD patients and control subjects has not shown any distinct
pathogenic mutation responsible for PD [90]. However, polymorph-
isms in human mtDNA conferring certain mtDNA haplotypes have
been indicated to inﬂuence the risk for developing PD [93–95,99,100]
and a polymorphism noted in a nuclear-encoded mitochondrial
complex I subunit could relate to the susceptibility to PD [99].
Recently, mutations/polymorphisms in mitochondrial transcription
factor A (TFAM) gene that regulates transcription of mtDNA and copy
number has been suspected for its association in PD [101,102].
Interestingly ablation of TFAM in nigrostriatal dopaminergic neurons
of mice is known to cause progressive loss of SNpc dopaminergic
neurons and L-DOPA responsive motor deﬁcits due to reduced mtDNA
expression and respiratory chain deﬁciency [103]. Another enzyme
regulating mtDNA replication is the mtDNA polymerase gamma 1
(POLG1). POLG1 is a nuclear encoded protein and imported into the
mitochondria to localize in the inner mitochondrial membrane.
Mitochondrial DNA synthesis, replication and repair are controlled
by POLG1 [104] and mutations might lead to mitochondrial pathology
and DNA deletions. It has been shown that mutations in POLG1 results
in a wide range of complex syndromes including autosomal dominant
or recessive progressive ophthalmoplegia and parkinsonism [105–
108]. PD associated with POLG1 mutations are L-DOPA responsive,
characterized by loss of SNpc dopaminergic neurons lacking Lewy
bodies, and by the presence of multiple mtDNA deletions and mtDNA
contents in muscle [105,109]. Muscle biopsies are also characterized
by reductions in the activities of mitochondrial complex I, III, and IV
[105,109]. However, it seems that POLG1 mutations do not always
necessarily result in PD. A study conducted on a large number of
sporadic PD patients from UK and Italy does not conform to the
possibility of linking common POLG1 polymorphisms in PD [110].
Overall in the present scenario the factors responsible for causing
abnormalities in mtDNA are unclear and also whether alterations in
mtDNA are a primary or secondary event in PD pathogenesis. Despite
these confounding and scanty evidences, the role of mtDNA cannot be
overruled and further investigations are warranted to better under-
stand its role in PD.
2.4. Mitochondrial permeability transition and PD
The mitochondrial permeability transition pore (PTP) phenom-
enon had been known and studied over more than 40 years but still
remains somewhat mysterious and enigmatic. In the recent decade, it
has drawn a renewed interest chieﬂy because of its perceived role in
cell death by either apoptosis or necrosis, which is extensively
reviewed elsewhere [111]. There are also numerous and recent
reviews detailing available evidences for the role of PTP in neural
cell death induced by ischemia, trauma, and various neurodegenera-
tive diseases [111–114]. However, we should emphasize here that
despite all this wealth of information, there is actually no strong and
unambiguous evidence supporting the role of PTP in any of
neurodegenerative disease at the level of organism.
The “classical” permeability transition pore (PTP) is a large channel
in the inner mitochondrial membrane which is normally closed and
can be opened by Ca2+ accumulation in mitochondria andmany other
factors. Opening of this channel renders mitochondria incapable of
ATP production and frequently results in severe damage to mitochon-
drial ultrastructure. The PTP is not merely a stochastic “damage” of
mitochondrial ultrastructure but a speciﬁc mechanism controlling the
permeability of the inner mitochondrial membrane. Several signature
features deﬁne this mechanism. In mammalian mitochondria, PTP has
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∼1500 D [115,116]. The opening of PTP is fully reversible in vitro
[116,117], whereas it can be opened and closed repeatedly without
extensive damage to mitochondria if the experimental conditions are
properly selected. In vitro, opening of the “classical” PTP results in a
large-amplitude mitochondrial swelling, an obligatory decrease in the
membrane potential [118,119] and, if allowed to stay open for some
time, results in eventual loss of matrix solutes such as NAD [120],
which inhibits the respiration of mitochondria, and GSH, which
stimulates ROS production [121]. The role of ROS in PTP activation is
somewhat controversial. Although many reports suggest that ROS can
induce PTP opening [118], almost all of these studies employed
exogenous oxidants added to mitochondria or cells. The role of
endogenously produced ROS in PTP opening remains to be elucidated
[122]. On the other hand, PTP opening stimulates ROS production by
isolated mitochondria [123,124] and in cells [125].
The molecular identity of the protein(s) that actually form the PTP
channel remains a mystery. Past studies identiﬁed several proteins
involved in the PTP formation or modulation, such as voltage
dependent anion channel (VDAC), adenine nucleotide transporter
(ANT), and more recently, mitochondrial phosphate transporter (PIC)
[126], though none of these proteins are currently thought to directly
form the PTP-channel [126–128]. Until recently, mitochondrial (ANT)
was viewed as the most likely candidate on the role of PTP-forming
protein [126,128]. ANT may also interact with another matrix protein,
cyclophilin D (CYPD) [129], which is a target of cyclosporine A.
Although the role of CYPD in modulating the Ca2+ threshold for PTP
activation had recently been strongly conﬁrmed [130–133], the role of
ANT in the PTP formation was strongly challenged [134]. To note, one
of the earliest observations implicating Ca2+-induced mitochondrial
dysfunction in PD-related cell death was that MPP+ with 6-
hydroxydopamine or dopamine strongly stimulated Ca2+ release
from mitochondria and hydrolysis of intramitochondrial pyridine
nucleotides [135]. This was followed by the ﬁnding that MPP+ caused
mitochondrial swelling and the release of cytochrome c [136], calcium
efﬂux andmembrane depolarization [137], all of which were inhibited
by cyclosporine A thereby implying a classical PTP. A monoamine
oxidase metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde,
induced PTP in mitochondria isolated from neural cells [138]. Also,
promethazine which is a weak PTP inhibitor [139], prevented the MPP
+-induced decrease in the mitochondrial membrane potential,
inhibited Ca2+-induced PTP in isolated brain mitochondria and
strongly reduced the loss of SN neurons [140]. Recently, we have
found that genetical ablation of PTP modulator cyclophilin D, which
signiﬁcantly increases the resistance of mitochondria to Ca2+-induced
PTP opening, also strongly protects mice from acute MPTP-neurotoxi-
city (Thomas et al., manuscript in preparation). Interestingly,
neuroprotective effect in the cyclophilin D null mice were only limited
to acute MPTP neurotoxic paradigm and not observed in sub-acute
MPTP neurotoxicity [141]. These ﬁndings suggest that cyclophilin D
mediates only acute-toxicity paradigms and may not play a role in
apoptosis seen in sub-acute regimen.
Thus, sufﬁcient evidence supports the induction of PTP by MPP+,
at least at the level of isolated brainmitochondria. As discussed earlier,
this PD toxin is an inhibitor of complex I, and in this regard it is very
interesting that complex I had long been implicated in themodulation
of PTP opening and it was suggested that complex I may be a part of
the PTP assembly [142]. However, given the complexity and
insufﬁcient knowledge of PTP composition and regulation, it is clear
that further research should answer some basic questions ﬁrst, such
as “what protein(s) form the PTP channel?”, “what proteins modulate
the PTP opening directly, by protein-protein interactions?”, “how to
assess and modulate the PTP status in vivo, in brain cells?”. Answering
these questions will immensely help to establish whether PTP plays a
role in the etiology of PD and develop therapeutic compounds
targeting PTP.3. Mitochondrial dysfunction and the genetic causes of disease
In the past decade, a rapidly expanding list of Mendelian-inherited
gene mutations has provided tremendous insight to the mechanisms
leading to loss of the nigrostriatal dopaminergic neurons in familial PD
which constitutes about less than 10% of the total PD cases. In recent
years, a plethora of studies channeled towards exploring the multi-
functional aspects of these Mendelian gene mutations point towards
their potential deleterious role in the disruption of mitochondrial
harmony and subsequent mitochondrial failure culminating in
neuronal dysfunction and death. We have brieﬂy highlighted below
the clinical association of ﬁve genes (α-synuclein, parkin, PINK1, DJ-1
and LRRK2) in PD that have been suggested to have a direct or indirect
role in mitochondrial dysfunction in disease pathogenesis.
3.1. α-synuclein
Missense mutations in α-synuclein gene (PARK1 & 4 locus) and in
addition to genomic triplications of a region of α-synuclein gene are
associated with autosomal dominant PD [143–146]. α-synuclein is a
ﬁbrillar aggregation prone protein which attains an increased
propensity to aggregate due to the presence of its hydrophobic non-
amyloid beta component domain. Fibrillar form ofα-synuclein forms a
major structural component of Lewy bodies and is believed to
contribute in PD pathogenesis due to a toxic gain of function.
Although both mitochondrial dysfunction and protein aggregation
are implicated in PD pathogenesis it was not clear until recently that
these two processes are interrelated and complement each other in
disease pathogenesis. New emerging evidences from both in vitro and
in vivo studies suggest a strong pathogenic role of α-synuclein in
causing mitochondrial dysfunction. Studies suggest that neurodegen-
eration observed in mice harboring human A53T α-synuclein mutant
is linked to mitochondrial damage. These mice show mitochondrial
accumulation of human α-synuclein and exhibit mitochondrial
degeneration associated with increased mtDNA damage and impaired
activity of the electron transport chain complex IV cytochrome
oxidase [147]. Overexpression of human α-synuclein in mice also
increases susceptibility to neurodegeneration following administra-
tion of mitochondrial toxins like MPTP and paraquat [148,149],
whereas loss-of-function of α-synuclein is known to promote
resistance to mitochondrial toxins like MPTP, 3-nitropropionic acid,
and malonate [150]. These ﬁndings suggest a complementary
relationship between expression of α-synuclein to inhibition of
mitochondrial functions considering that administration of mitochon-
drial electron transport chain inhibitors in rodents and in cell culture
systems are known to cause aggregation and formation of α-synuclein
inclusions [71,151–153]. There is also data suggesting that inhibition of
the ubiquitin proteasomal pathway in vitro leads to accumulation of
unfolded proteins causing mitochondrial dysfunction and mitochon-
drial dependent cell death suggesting that both mitochondrial
dysfunction and protein aggregation may have convergent mechan-
isms leading to neurodegeneration [154]. A possible connection
between mitochondrial dysfunction and protein aggregation as in
the case of α-synuclein could be explained by the fact that α-synuclein
is a modulator of oxidative stress. Consistent with this notion more
than twofold increases in speciﬁc carbonyl levels of three metabolic
proteins such as carbonic anhydrase 2, alpha-enolase, and lactate
dehydrogenase 2 in brains of human A30P α-synuclein transgenic
mice were reported. These ﬁndings imply that proteins associated
with impaired energy metabolism and mitochondria are particularly
prone to oxidative stress associated with mutant α-synuclein [155]
Additionally, presence of α-synuclein mutations may signiﬁcantly
modify proteomic organization in vivo that may in turn affect multiple
cell survival pathways to impact disease development. A recent study
in presymptomatic A53T α-synuclein ﬂy model of PD using global
isotopic labeling strategy combined with multidimensional liquid
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changes in protein interaction networks [156]. These changes in
normal proteomic organization resulted in improper functioning of
multiple pathways in addition to mitochondrial defects to induce PD.
Together, these data suggests that on one hand formation of α-
synuclein inclusions could be initiated by an impaired mitochondrial
function whereas on the other hand impaired mitochondrial function
may result in abnormal protein aggregation. However, precisely
how these two processes are linked to each other and is associated
with the pathogenesis of disease process warrants a more detailed
investigation.
There is also a great deal of interest amongst researchers to identify
whether α-synuclein associates with mitochondria during pathologic
conditions to disrupt mitochondrial integrity. A recent study showed
that the N-terminal 32 amino acids of human α-synuclein contain a
cryptic mitochondrial targeting signal, which is crucial for mitochon-
drial targeting of α-synuclein [157]. Mitochondrial targeted α-
synuclein was shown to predominantly associate with the inner
mitochondrial membrane whereas α-synuclein lacking the mitochon-
drial targeting signal failed to associate with the mitochondria.
Interestingly accumulation of α-synuclein in the mitochondria of
human dopaminergic neurons caused reduced mitochondrial com-
plex I activity and increased production of ROS which was not
observed in α-synuclein lacking the mitochondrial targeting signal.
Investigation of mitochondria from SN, striatum, and cerebellum of
postmortem PD patients and controls showed the constitutive
presence of α-synuclein in the mitochondria of all three brain regions
from normal subjects. Interestingly, mitochondria isolated from SN
and striatum but not cerebellum from PD subjects showed signiﬁcant
accumulation of α-synuclein and decreased complex I activity. Blue
native gel electrophoresis and immunocapture analysis further
revealed the association of α-synuclein with mitochondrial complex
I suggesting that pathological consequences such as complex I
inhibition might be associated due to mitochondrial accumulation of
α-synuclein [157]. It will be of great importance to understand what
triggers the mitochondrial translocation of α-synuclein in addition to
its mitochondrial targeting by the cryptic mitochondrial targeting
signal. A possible mechanism is suggested to be improper cytosolic
environment during cellular abnormalities with oxidative stress being
a major culprit. A recent study demonstrated that cytosolic acidiﬁca-
tion induces translocation of α-synuclein from the cytosol to
mitochondria. This translocation of α-synuclein was shown to occur
rapidly under artiﬁcially-induced low pH conditions and especially as
a result of pH changes during oxidative or metabolic stress.
Interestingly α-synuclein binding was shown to be facilitated by low
pH-induced exposure of the mitochondria-speciﬁc lipid cardiolipin.
These results imply a direct role for α-synuclein in mitochondrial
physiology, especially under pathological conditions [158].
Thus both genetic and biochemical abnormalities in α-synuclein
lead to its physical associationwithmitochondria. This in turn impacts
mitochondrial physiology to affect normal functioning of dopaminer-
gic neurons. The focus now should be on how these factors are
interrelated to provide a cause and effect relationship to development
of PD due to abnormalities in α-synuclein.
3.2. Parkin
Mutations in the parkin gene (PARK2) were reported to cause early
onset juvenile form of autosomal recessive parkinsonism [159]. Parkin
mutations serve as themost common cause of young onset PD, although
mutations in patients with delayed-onset cases have also been reported
[160,161]. Parkin is a RING ﬁnger containingprotein and has been shown
to function as an ubiquitin E3 ligase in vitro [162]. It is known tomediate
polyubiquitination reaction to clear aggregation prone substrates for
proteasomal degradation, and the loss of its E3 ligase activity has been
suggested to result in accumulation of toxic substrates leading toautosomal recessive form of PD [163]. In addition to its role in the
proteasomal machinery more recent studies have suggested a role of
parkin in mediating proteasomal independent polyubiquitination of
lysine 63-linked process or even monoubiquitination [164]. Such
modiﬁcations are known to mediate functions involved in transcrip-
tional regulation, protein trafﬁcking and neuroprotective signaling
[165,166]. Numerous studies indicate that a potential function of par-
kin might be in the mitochondria. Although parkin protein is
ubiquitously expressed, subcellular fractionation studies demonstrate
that parkin is associated with the outer mitochondrial membrane
[167,168] suggesting a potential role in modulating mitochondrial
functions. In dividing SH-SY5Y neuroblastoma cells parkin is localized
to themitochondriawhereasupondifferentiation it translocates toGolgi
apparatus and also nucleus. This phenomenon of parkin departing the
mitochondria and locating itself to other intracellular structures is also
observed when cells are treated with inhibitors of electron transport
chain suchas rotenone,mitochondrial uncouplers andcell cycle blockers
[169]. It was further demonstrated that this mitochondrial export of
parkin is mediated by opening of the mitochondrial permeability
transition pore. Interestingly upon transient transfection, wild type
parkin seems to be imported into themitochondriawhereas the amount
of protein import was much less when cells were transfected with
parkin mutants. Kuroda and colleagues also demonstrated a novel
function of parkin whereby overexpression of parkin resulted in
transcription and replication of mtDNA in proliferating cells, a
phenomenon blocked by knockdown of parkin by siRNA. Transcription
of mtDNA in proliferating cells was a result of direct functional
association of parkinwith TFAM. These data suggests parkin is involved
in mitochondrial transcription and replication. In vivo studies also
support a potential role of parkin in the mitochondria. Gene knockouts
of parkinmouse and ﬂies are known to exhibit dramatic mitochondrial
defects [68,170]. These include swollen mitochondria, severely frag-
mented cristae, decreased abundance of several proteins subunits of the
mitochondrial electron transport chain complex I and IV, and decre-
ments in mitochondrial respiratory capacity [68,170]. In contrast to
parkin knockout mouse models the mitochondrial abnormalities in
drosophila models representing loss of parkin function show dopami-
nergic neurodegeneration, reduced lifespan, and increased apoptosis in
ﬂight muscles [171,172].
One possible function of parkin in the mitochondria might be to
maintain normal antioxidant status. Downregulation of parkin in PC12
cells resulted in a signiﬁcant decrease in reduced glutathione levels
and superoxide dismutase activity [173]. In parkin mutant ﬂies
dopaminergic neurodegeneration is enhanced by loss-of-function
mutations of the glutathione S-transferase S1 (GstS1), a rate limiting
enzyme in glutathione synthesis [174]. Dopaminergic neurodegenera-
tion observed in parkin mutant ﬂies were signiﬁcantly suppressed by
overexpression of GstS1 suggesting that parkin might be involved in
regulation pathways responsible for glutathione metabolism. This is
also consistent with the ability of allyl disulﬁde and sulphorphane,
activators of phase II detoxifying genes to rescue dopaminergic
neurodegeneration in parkin mutant ﬂies by directly affecting
abundance of reduced glutathione levels [175]. In SH-SY5Y cells
transcriptional induction of tyrosinase causes overproduction of
intracellular dopamine and its oxidative metabolites leads to
increased generation of both cytosolic and mitochondrial reactive
oxygen species to cause apoptosis. Stable expression of wild type, but
not mutant parkin in these cells resulted in blockade of tyrosinase-
induced apoptosis. Wild type parkin signiﬁcantly attenuated the
tyrosinase-induced activation of c-Jun N-terminal kinase (JNK) and
p38 mitogen-activated protein kinase signaling whereas PD asso-
ciated parkinmutants failed to attenuate tyrosinase induced activation
of stress activated protein kinase signaling and subsequent apoptosis
[176]. These in vitro ﬁndings further gains support from in vivo ﬂy
models where the JNK is strongly activated in the dopaminergic
neurons of parkin mutant ﬂies and the activation of the JNK signaling
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tyrosine hydroxylase level and impaired locomotion. Consistent with
this, both epistatic analysis and mammalian cell studies showed that
parkin inhibits the JNK signaling pathway in an E3 ligase activity-
dependent manner [177]. This suggests that parkin may play crucial
role in mitochondria dependent stress signaling pathway in impacting
apoptosis. Further evidence to its role in apoptosis is strengthened
from studies where inducible overexpression of parkin has been
shown to delay ceramide-induced mitochondrial swelling leading to
blockade of cytochrome c release and subsequent caspase 3 activation
in differentiated PC12 cells [167]. Interestingly, apoptosis was
abrogated in these cells by disease-causing mutants and treatment
with proteasome inhibitor suggesting a role of parkin in mitochondria
dependent cell death. The mitochondrial dependence of parkin in
impacting cell death is also consistent with ﬁndings where treatment
of midbrain dopaminergic neuronal cultures showed increased
susceptibility to mitochondrial complex I inhibitor rotenone-induced
death [178]. Similar effects have also been observed in primary
cultures from skeletal muscle derived from parkin knock-out mice,
where absence of parkin resulted in greater sensitivity to cytotoxicity
following treatment with mitochondrial complex I inhibitor rotenone
and a mitochondrial uncoupler carbonyl cyanide 3-chlorophenylhy-
drazone [179]. Interestingly, severe mitochondrial respiratory chain
deﬁcits have also been detected in peripheral leukocytes taken from
human PD patients with parkinmutations [180]. Taken together these
observations provide convincing evidence for a major role of parkin in
directly regulating mitochondrial functions that probably is evolutio-
narily conserved.
Parkin has also been shown to be instrumental in rescuing
mitochondrial dysfunction caused due to pathogenic mutations
associated with familial PD. This includes mitochondrial dysfunction
due to α-synuclein overexpression and PINK1 loss-of-function. Loss of
parkin function has been shown to exacerbate mitochondrial damage
in α-synuclein transgenic mice [181]. The mitochondrial damage in
these double mutant mice with α-synuclein overexpression and par-
kin deﬁciency includes mitochondrial morphological alterations and
reduced complex I mediated mitochondrial respiration in substantia
nigra. This suggests that parkin deﬁciency may provide increased
vulnerability to alterations in mitochondrial functions due to α-
synuclein overexpression. Although it is yet to be determined how
parkin is involved in these mitochondrial functions. Drosophila
PINK1 mutants exhibit increased sensitivity to mitochondrial stress
with reduced ATP levels and mtDNA content. Similar to parkinmutant
ﬂies mitochondria in PINK1 mutant ﬂight muscles are swollen with
fragmented cristae [182–184]. Furthermore, parkin overexpression
can rescue mitochondrial alterations induced due to loss of human
PINK1 [185]. These studies further demonstrated that mutant PINK1
associated mitochondrial dysfunctional phenotype was remarkably
reversed by overexpression of parkin. It is yet unclear how parkin
rescues these mitochondrial anomalies. PINK1 and parkin has been
shown to physically interact in neurobalstoma cell lines [164]
although the functional implications of such interactions are unclear.
It might be possible that PINK1 being a kinase might regulate parkin
function postranslationally either by direct phosphorylation or by
other signalingmechanisms. Additionally, a recent study suggests that
parkin plays a concerted role with PINK1 in regulating mitochondrial
dynamics through the mitochondrial ﬁssion process [186]. The fact
that parkin can rescue PINK1 loss-of-function associated mitochon-
drial abnormalities unequivocally suggests an inherent role of parkin
in the maintenance of mitochondrial functions.
3.3. PINK1
Mutations in phosphatase and tensin homologue (PTEN)-induced
putative kinase 1 (PINK1) cause a rare form of autosomal recessive PD
[187]. Postmortem brains of PD patients with PINK1 heterozygousmutations display nigrostriatal neuronal loss with Lewy bodies [188].
Nuclear encoded PINK1 gene is translated in the cytoplasm and
imported into the mitochondria through an N-terminal mitochondrial
targeting sequence, and bears a kinase domain to function as a serine/
threonine kinase [187,189]. PINK1 mutations are believed to result in
impaired phosphorylation of its substrates probably in the mitochon-
dria to cause PD. The sub-mitochondrial localization of PINK1 has been
intensely debated which is crucial for identifying the physiological
substrates of PINK1 and its mode of action in the context of PD
pathogenesis. The majority of studies demonstrate that PINK1
localizes in the inner mitochondrial membrane [188–190], whereas
others suggest that PINK1 associates with the intermembrane space
[76,189,190] or even the outer mitochondrial membrane [188] with
the kinase domain facing the cytoplasm [191].
Accumulating evidence suggests that PINK1 mutations may result
in the loss of PINK1 function resulting in PD [192–194]. There are
numerous in vivo studies which support this notion. In Drosophila,
loss of PINK1 function produced mitochondrial morphological defects
such as fragmented cristae, increased sensitivity to oxidative stress,
loss of nigrostriatal dopaminergic neurons and apoptotic ﬂight muscle
degeneration [182–184]. The pathological phenotype observed in
PINK1 mutant ﬂies resembled those of parkin mutant ﬂies. Over-
expression of parkin has been shown to block mitochondrial
dysfunction and associated pathology due to PINK1 loss-of-function.
This suggests that both parkin and PINK1 share common mechanistic
pathways in impacting mitochondrial dysfunction in vivo with parkin
acting downstream of PINK1 [182–184]. Recently, mice deﬁcient in
PINK1 demonstrated signiﬁcant mitochondrial defects such as
impaired mitochondrial respiration, and signiﬁcant defects in com-
plex I and also complex II-IV activity in the striatum of younger
animals. Interestingly these mitochondrial functions were normal in
the cerebral cortex of younger animals but they were signiﬁcantly
impaired in the older animals suggesting that aging in addition to
PINK1 loss-of-function might inﬂuence mitochondrial respiration.
These changes were also accompanied by signiﬁcantly reduced
activity of the Krebs cycle associated enzyme aconitase. Loss of
PINK1 also showed increased exacerbation to mitochondrial respira-
tion upon exposure to oxidative stressors such as H2O2 and mild heat
shock. This suggests that mitochondrial dysfunction together with
increased oxidative stress may result in dysfunction of nigrostriatal
dopaminergic neurons [195]. These mice also result in impaired
dopamine release and synaptic plasticity in the striatum which is
crucial for normal dopamine neuronal function especially during
disease condition [196]. Interestingly, mitochondrial pathology and
respiratory chain defects were detected in the peripheral tissues in PD
patients with PINK1mutation [197]. Recently, a PD patient with PINK1
mutation demonstrated defects in mitochondrial respiratory and ATP
synthesis in ﬁbroblasts [198] suggesting an unequivocal role of PINK1
in mitochondrial function. In vitro studies, using various cell lines,
demonstrate that an overexpression of wild type PINK1, but not PD-
linked PINK1 mutants inhibited mitochondrial cytochrome c release
and blocked neuronal apoptosis [199,200]. Downregulation of PINK1
in human cell lines by RNA interference results in abnormal
mitochondrial morphology and reduced mitochondrial membrane
potential which were rescued by wild type PINK1 but not PD
associated mutants [185]. Interestingly, aberrant mitochondrial
morphologies such as swollen, truncated and fragmented mitochon-
dria were also observed in ﬁbroblasts cells from patients carrying the
Q126P and G309D PINK1 mutations suggesting a role of PINK1 in
maintenance of mitochondrial integrity [185].
The cytoprotective role of PINK1 has been demonstrated by studies
using cellular and in vivo models of PD. Loss of PINK1 function by
siRNA resulted in increased sensitivity to MPP+-toxicity in primary
cortical neurons which were abrogated by overexpression of wild type
PINK1 [201]. This protective effect of PINK1 overexpression was
mediated by its kinase domain which was abolished by PD-associated
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adenoviral overexpression of PINK1 in midbrain dopaminergic
neurons rescued toxicity against the parkinsonian neurotoxin MPTP
[201]. Interestingly, the cytoprotective phenotype of PINK1 was
achieved merely by the presence of cytosolic PINK1 lacking a
mitochondrial targeting sequence. These results are indicative of the
crucial role of cytoplasmic PINK1 rather a mitochondrial kinase in
impacting its cytoprotective function. To further emphasize this
phenomenon a recent study showed that PINK1 localization in the
mitochondria spans the outer mitochondrial membrane, with the N-
terminus being inside the mitochondria, whereas the C-terminal
kinase domain faces the cytosol [191]. This pattern of PINK1 assembly
may provide clues to its interaction with other cytosolic proteins such
as parkin and also other substrates of PINK1.
Recently, two potential substrates known to mediate PINK1 anti-
apoptotic function were identiﬁed. These include a) TNF receptor-
associated protein 1 (TRAP1), a mitochondrial molecular chaperone
also known as heat shock protein 75 [190] and b) HtrA2, a
mitochondrial serine protease, also known as Omi which is also a
candidate gene for PARK13 [76]. In vitro studies by Pridgeon et al.,
suggests that PINK1 binds and associates with TRAP1 in the
mitochondrial intermembrane space and the innermembrane. Addi-
tionally, using a kinase assay PINK1 was shown to phosphorylate
TRAP1 in test tubes and also in cell models. In cells, TRAP1
phosphorylation by PINK1was shown to prevent cytochrome c release
and apoptotic cell death induced by H2O2. Furthermore disease-linked
and kinase mutants of PINK1 were unable to phosphorylate TRAP1 to
promote cell survival, while absence of TRAP1 prevented the ability of
wild type PINK1 to protect cells against apoptosis. The TRAP1 mode of
action in inhibiting mitochondrial cytochrome c release is unknown
but it seems that TRAP1 acts downstream of PINK1 to block apoptosis.
Plun-Favreau and colleagues identiﬁed the mitochondrial serine
protease HtrA2, also known as Omi, as a putative binding partner of
PINK1. The functional interaction between Omi and PINK1was brought
about by phosphorylation of Omi by the p38-kinase in the presence of
a functional PINK1. Interestingly the phosphorylation of Omi was
completely absent in postmortem brain tissue from patients who
developed PD due to PINK1 mutations. The Omi phosphorylation was
able to rescue mouse embryonic ﬁbroblasts against PD-causing toxins
such as 6-hydroxydopamine, rotenone and other stressors causing
apoptosis. These cytoprotective effects of Omi was abolished by PD
causing PINK1 mutations suggesting that Omi functions downstream
of PINK1 to rescue against mitochondrial cell death. This is in
agreement with Omi in rescuing against mitochondrial dysfunctions
leading to PD [202] since during apoptosis Omi is released from the
mitochondrial intermembrane space to the cytosol to act on the IAPs
(inhibitor of apoptosis) to activate the caspases downstream.
Additionally Omi is known to degrade unfolded mitochondrial
proteins to serve as a protein-quality control agent. The identiﬁcation
of both TRAP1 and Omi as potential substrates for PINK1 and that
these substrates cooperate with PINK1 to rescue mitochondrial
apoptosis against stressors further reinforce the role of mitochondrial
dysfunction in neurodegeneration associated with PD. However, it is
yet to be determinedwhether TRAP1 and Omi are authentic substrates
in vivo and if yes, how they inﬂuence loss of PINK1 in PD.
More recently PINK1 has also been shown to play a role in the
process of mitochondrial dynamics by interacting with proteins
involved in the ﬁssion and fusion machinery. The mitochondrial
ﬁssion is a process controlled by drp1 (dynamin related protein 1) and
FIS1 (mitochondrial ﬁssion protein) involving separation of mito-
chondrion into two or more smaller parts where as mitochondrial
fusion controlled by Mitofusin (mfn) and Optic atrophy 1 (OPA1)
involves combination of two mitochondria into a single organelles. A
balance between ﬁssion and fusion machinery is crucial for the
normal mitochondrial function. PINK1 has been suggested to promote
mitochondrial ﬁssion and to regulate mitochondrial morphology inDrosophila and several mammalian models [186,203,204]. Genetic
manipulations in drosophila by overexpression of drp1 protein known
to promote mitochondrial ﬁssion and knockdown to mfn and OPA1
that inhibit mitochondrial fusion has been shown to suppress PINK1
mutant phenotype of dopaminergic neurodegeneration and loss of
ﬂight muscles [186,203]. On the other hand some studies also point
toward a signiﬁcant role of mitochondrial fusion proteins in rendering
neuroprotective phenotype in models of oxidative stress and
mitochondrial stressors [205,206]. These suggest that it is very
premature to determine if mitochondrial ﬁssion and/or fusion may
play a deﬁnitive role in PD pathogenesis and requires further
exploration.
3.4. DJ-1 and LRRK2
DJ-1mutations associated with PD are rare and account for 1–2% of
early onset forms of the disease [207]. Several in vitro and in vivo
studies demonstrate that silencing DJ-1 increases susceptibility to cell
death whereas overexpressing DJ-1 provides cytoprotective effects
against cell death. The cytoprotective effect of DJ-1 seems to be
speciﬁc for death due to oxidative stress but not to non-oxidative
stresses, since DJ-1 knockout ﬂies show increased sensitivity to H2O2
and the redox cycler paraquat [208,209]. The modiﬁcation of cysteine
residues on DJ-1 to cysteine-sulﬁnic and cysteine-sulfonic acids under
oxidative conditions is suggested to be required for its cytoprotective
action during oxidative stress-induced cell death [208,210,211]. It is
thus suggested that DJ-1 functions as a redox sensor to exert
protective effects by undergoing cysteine modiﬁcations on DJ-1.
Recent studies also suggest that DJ-1 may exert neuroprotective
effects through several different mechanisms especially by acting as a
transcriptional coactivator, a protease or a molecular chaperone [148].
At this juncture, unlike parkin and PINK1, evidence for the role of DJ-1
in mitochondrial function is minimal. Endogenous DJ-1 is localized to
mitochondrial matrix and the intermembrane space although a
predominant portion of DJ-1 localizes to the cytosol and a small
fraction in the nucleus [212,213]. It is believed that the mitochondrial
localization of DJ-1 might suggest a potential role in mitochondrial
functions. There is evidence that DJ-1 functions as an atypical
peroxiredoxin-like-peroxidase and that loss of this function results
in an impaired mitochondrial ROS scavenging [214]. In conjunction
with this, mice lacking DJ-1 are more susceptible to dopaminergic
neurotoxicity and oxidative stress induced by MPTP [215]. Also
nigrostriatal dopaminergic neurons were highly vulnerable to para-
quat in DJ-1 deﬁcient mice, the toxicity being associated with lowered
ATP levels and inhibited proteasomal function [216]. However the
exact role ofDJ-1 inmitochondria and the importance of mitochondria
in developing such phenotypes remain to be established. It has been
shown that during oxidative stress DJ-1 is upregulated and translo-
cates to the mitochondria [217], where its functional form resides as a
dimmer [213]. Mitochondrial targeted DJ-1 showed increased protec-
tion against oxidant induced cell death by functioning as an
antioxidant. However, it is yet to be determined if DJ-1 undergoes
such dynamic regulation in vivo to render its antioxidant action in the
mitochondria. It was recently demonstrated that DJ-1 functions to
rescue against oxidative stress by its RNA binding ability in an
oxidation dependent manner to modulate functioning of mitochon-
drial genes and genes involved in glutathione metabolism and other
generic cytoprotective signaling [218]. This suggests a possible
universal mechanism by which DJ-1 may defend against cytotoxicity
during oxidative stress and mitochondria associated cell death. There
is also evidence from in vitro studies that DJ-1 physically interacts
with familial PD linked genes such as PINK1 [219] and with parkin
during oxidative stress [220] but such phenomenon and their
implications to disease pathogenesis is yet to be proven in vivo. A
possible function of the association of DJ-1 with parkin and PINK1
might be to alleviate oxidative stress during mitochondrial
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studies where loss-of-function of PINK1 and parkin mediated
neurodegeneration in ﬂies can be alleviated by overexpression of
antioxidant enzymes [174,221]. Since defective functioning of parkin
and PINK1 lead to mitochondrial dysfunction and increased ROS
production a plausible function of DJ-1 is suggested to act as a sensor
for oxidative stress associated with mitochondrial respiration [222].
Mutations in leucine-rich repeat kinase 2 (LRRK2) gene cause
autosomal dominant PD [223,224]. This gene has obtained consider-
able attention because of the presence of LRRK2 mutations beyond
familial cases of disease with evidence of partial penetrance which is
age dependent. LRRK2 encodes a 2527 amino acid multidomain,
280 kDa protein belonging to ROCO protein family that includes a Rho/
Ras-like GTPase domain, a protein kinase domain of the MAPKKK
family, as well as aWD40-repeat and a leucine-rich repeat domain. An
additional domain C-terminal to the GTPase domain, termed COR (for
carboxy-terminal of Ras), is of unknown function. Point mutations
have been found in almost all of the identiﬁed domains. The presence
of mutations in several different domains, as well as the lack of
deletions or truncations, along with dominant inheritance, is con-
sistent with a gain-of-function mechanism. The precise physiological
role of this protein is unknown but the presence of multiple functional
domains suggests involvement in a wide variety of functions. A
possible mechanism of LRRK2 action is at mitochondria. There is
evidence from subcellular fractionation studies that about 10% of
LRRK2 is associated with the mitochondrial fraction [225]. Another
study showed an association of LRRK2 with TOM20, a marker of the
outer mitochondrial membrane [226]. The strongest evidence for
localization of LRRK2 to mitochondria comes from a recent immuno-
histochemical study [227]. The authors generated polyclonal anti-
bodies to the amino or carboxy termini of LRRK2 to examine the
subcellular and immunohistochemical distribution of LRRK2. The
subcellular fractionation studies showed the presence of LRRK2 in
microsomal, synaptic vesicle-enriched and synaptosomal fractions
from rat brain including mitochondria. Since, as discussed above,
mitochondria are implicated in the pathogenesis of PD, the localization
of LRRK2 to mitochondria could play a critical role in PD pathogenesis.
Overall, familial gene products which reside in themitochondria or
elsewhere in the cell could be crucial players in the maintenance of
mitochondrial homeostasis. Deleterious mutations affecting the vital
functions of these proteins therefore could dysregulate mitochondrial
functions by interaction through a maze of signaling pathways. Based
on the evidences of intensive studies conducted in vivo and in vitro to
resolve the impact of gene or environment or a complex interaction of
both in PD might eventually expose mitochondria as the responsible
personnel in the neuronal death in PD.
4. Concluding remarks and future perspectives
Ample empirical evidence as detailed in this review suggests a
major role of mitochondrial dysfunction in the pathogenesis of PD.
Deﬁcits in mitochondrial complex I activity in combination with
increased oxidative stress, and aging associated damage to mitochon-
drial DNA are currently known to dominate as key biochemical
abnormalities associated with pathogenesis of sporadic PD. Factors
that potentially trigger these mitochondrial abnormalities which
ultimately lead to PD are still elusive. It is suggested that mitochon-
drial anomalies could result from exposure to environmental factors
such as pesticides and other daily use chemicals that have been shown
to cause PD both in humans and animal models. In addition familial
mutations result in PD due to mitochondrial dysfunction that includes
complex I deﬁcits, increased ROS production, and impaired mitochon-
dria-dependent cytoprotective signaling cascades. Together these
further reinforce and validate the importance of mitochondrial
functions not only is sporadic PD but also in familial forms of the
disease. Although much is known about the familial gene mutationsand their impact on mitochondrial functions, a deﬁnitive mitochon-
drial pathway in disease pathogenesis due to these mutations is yet to
emerge. Based on the current knowledge of mitochondrial alterations
in sporadic and familial PD it could be speculated that strategies aimed
at correcting the above mentioned biochemical abnormalities might
be useful to halt or slowdown the progression of PD. In this regard
some of the candidate drugs which showed great efﬁcacy in
experimental models of PD have already made it to clinical trials.
Preliminary clinical trial data on CoenzymeQ10 and creatine known to
act by improving mitochondrial electron transport chain functions
have shown some promise. There is also a great deal of enthusiasm
due to recent identiﬁcation of novel mitochondrial targets such as
PGC-1α (peroxisome proliferator-activated receptor gamma co-
activator) and the sirtuin family of enzymes that are known to
modulate aging, mitochondrial biogenesis, metabolic homeostasis and
mitochondria-dependent cell death. These observations hold promise
for future development of neuroprotective strategies in PD by
targeting mitochondrial dysfunction. It is important to remember
that PD is amulti-factorial disease andmitochondrial dysfunctionmay
only be a part of this complex process. Future research should thus
focus on developing neuroprotective strategies by targeting multiple
pathways involved in disease process including those targeted to
alleviate mitochondrial dysfunction in PD.
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